Depomed, Inc. (DEPO) Traders Should Start Listening to Analysts

Depomed, Inc. (NASDAQ:DEPO) shares saw a recent bid of $6.26 and 2.9M shares have exchanged hands in the recent trading session, yielding a -35.79% decline over the past week.DEPO price increased 3.99% or $-0.24 versus $6.02 at the end of the prior session. This change led market cap to move at $405.84M, putting the price -76.83% below the 52-week high and 5.21% above the 52-week low. The company’s stock has a normal trading capacity of 1.84M shares while the relative volume is 1.58.

Is Depomed, Inc. (NASDAQ:DEPO) Worth Buying?

By historical standards, Depomed, Inc. (NASDAQ:DEPO) remains a cheap stock. DEPO’s current price-earnings ratio amounts above the average P/E ratio of 31.30 times earnings. For now, DEPO is the toast of Wall Street as its ABR stands at 2.50 with 0 out of 8 analysts rating the stock a buy. Over the short term, some market observers may have noticed that It has a 18.16% short float with 15 days to cover. The Stock becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Company has far performed well this year, with the share price down -65.26% since January. Over the past 2 quarters, Depomed, Inc. (NASDAQ:DEPO) is down -63.11%, compared with a fall of nearly -46.17% for 3 months and about -39.63% for the past 30 days.

Depomed, Inc. (DEPO) Has Mean Target Price of $10.00

To stay one step ahead we extended our research by comparing different price targets. Depomed, Inc. (NASDAQ:DEPO) notched a 12-month high of $9.57 while $12.00 target is by far the most aggressive out of analysts who are currently evaluating DEPO, $2.43 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $5.00, which would be decrease of about -20% of its current value. The mean target of $10.00 should be compared with the price when the stock was languishing around $5.95 a share. And it remains to be seen which target price DEPO can achieve without sacrificing much as the company is holding a -70.36% fall for the past twelve months.

Depomed, Inc. Revenue Estimate is $410.09 Million

Last time, the company shocked Wall Street by reporting EPS of $0.08, smashing the consensus of $0.08 per share. Revenue for the quarter also killed consensus, coming in at $100.46 Million, compared to the consensus of 100.36 Million. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $0.12. The company is expected to report EPS as high as $0.21 and as low as $-0.14 per share. Similarly, full-year EPS forecasts have ranged between $0.25 and $0.65. The mean EPS estimate is $0.51. On the other side, sales forecasts for the current quarter are $104.53 Million. The stock is expected to report revenue as high as $108.98 Million and as low as $100.25 Million per share. Similarly, full-year sales forecasts have ranged between $402.9 Million and $418.65 Million. The mean revenue estimate is $410.09 Million.

Over the last 5 years, Depomed, Inc. has averaged a -25.80% YoY EPS growth rate and a 27.90% revenue growth rate. Analysts are expecting EPS growth rates to be at -14.90% this quarter and EPS estimate for next year reflect 49.85% growth rate.

What Guru’s think About Is Depomed, Inc. (NASDAQ:DEPO)

Sell-side analysts also have something to say about this DEPO. RBC Capital Mkts analysts stated on 08/08/2017 that they maintained their Sector Perform rating. Morgan Stanley had a markedly different take on 08/08/2017, proposing that DEPO is now considered Underweight versus prior Equal-Weight rating. Piper Jaffray raised its rating on Depomed, Inc. to Neutral on 10/05/2017 in a reversal from its prior Underweight rating. RBC Capital Mkts analysts stated on 29/03/2017 that they maintained their Sector Perform rating.

Leave a Reply

Your email address will not be published. Required fields are marked *